Efavaleukin alfa

N/A

Report date: 2024/11/28 20:00:07

Base Information

Drug NameEfavaleukin alfa
Drug Alias NameAMG-592
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionImmunomodulatorsInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsInflammationGraft vs Host DiseaseLupus Erythematosus, Systemic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[32] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesN/A
Active IndicationsInflammationLupus Erythematosus, Systemic
Inactive IndicationsGraft vs Host DiseaseColitis, UlcerativeArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A